ABSTRACT
In this paper, we describe the main outcomes of AGILE (acronym for "Adaptive Gateways for dIverse muLtiple Environments"), an EU-funded project that recently delivered a modular hardware and software framework conceived to address the fragmented market of embedded, multi-service, adaptive gateways for the Internet of Things (IoT). Its main goal is to provide a low-cost solution capable of supporting proof-of-concept implementations and rapid prototyping methodologies for both consumer and industrial IoT markets. AGILE allows developers to implement and deliver a complete (software and hardware) IoT solution for managing non-IP IoT devices through a multi-service gateway. Moreover, it simplifies the access of startups to the IoT market, not only providing an efficient and cost-effective solution for industries but also allowing end-users to customize and extend it according to their specific requirements. This flexibility is the result of the joint experience of established organizations in the project consortium already promoting the principles of openness, both at the software and hardware levels. We illustrate how the AGILE framework can provide a cost-effective yet solid and highly customizable, technological foundation supporting the configuration, deployment, and assessment of two distinct showcases, namely a quantified self application for individual consumers, and an air pollution monitoring station for industrial settings.
ABSTRACT
The aim of the study was to assess the activity and tolerability of the combination of gemcitabine (GEM) and vindesine (VDS) in elderly or poor performance patients with advanced non-small cell lung cancer. Forty four patients (36 males and 8 females with a median age of 70 years and a median Karnofsky performance score of 60) were recruited between January 1998 and June 2001; 9 (20.5%) were stage IIIB patients and 35 (79.5%) were stage IV patients; 20 (45.5%) had squamous carcinoma and 24 (54.5%) non-squamous carcinoma. The patients received GEM 1000 mg/m(2) and VDS 3mg/m(2) (max 5mg) on days 1 and 8 every 3 weeks, and were all evaluable for response and toxicity: 17 (38.6%) were partial responders, 17 (38.6%) experienced stable disease, and 10 (22.3%) progressive disease. Grade 3-4 anemia, neutropenia and thrombocytopenia were observed in, respectively, 6.8, 9.1 and 2.3% of the patients, and grade 2-3 fatigue, paresthesias and skin toxicity in, respectively, 11.4, 20.4 and 2.3%. After a median follow-up of 54 months, 43/44 patients died; median survival was 12 months, and a clinical benefit was observed in 54.5% of cases. GEM plus VDS is an active and well-tolerated schedule.
